FDA Plans to Speed Up Nicotine Pouch Approvals: What's Changing (2026)

By PouchGuide Editorial Team · Published September 25, 2026

In late September 2026, The Wall Street Journal reported that the US Food and Drug Administration is preparing to change how it reviews new tobacco products. The aim is to let nicotine pouches, e-cigarettes and similar products get authorized faster. As of this writing, the FDA had not yet made a formal announcement, so treat the details below as reported plans, not final rules.

Here’s what the current system is, what’s expected to change, and what it could mean if you buy nicotine pouches in the US.

How nicotine pouches get authorized today

Every new tobacco product sold in the US, including tobacco-free nicotine pouches, needs FDA authorization. The main route is a Premarket Tobacco Product Application (PMTA). The company has to show that allowing the product on the market is “appropriate for the protection of the public health”. That means weighing the likely benefit to adults who switch from cigarettes against the risk of new users, especially young people, taking it up.

The rules for what goes into a PMTA were set by a final rule in October 2021. Applications must cover the product’s ingredients and design, manufacturing, health risks, likely effects on the population, and environmental impact. That’s a lot of science, and reviews have historically taken a long time.

The result is a small list of authorized pouches. According to the FDA, 30 nicotine pouches had been authorized as of August 2026, up from 20 when the agency launched its pouch pilot in September 2025. Many pouches sold in stores today are still waiting on a decision, or were never authorized at all. For a plain-English guide to the different types of FDA decisions, see our explainer on MGOs vs MRTP orders.

The 2025 pilot that came first

The reported overhaul didn’t come out of nowhere. On September 18, 2025, the FDA launched a pilot program for nicotine pouch applications. The pilot focused reviews on “the most critical elements” for pouches and added more real-time communication between FDA staff and applicants. The goal was to fix problems during the review instead of sending long deficiency letters at the end.

The FDA says the pilot worked. In an August 2026 update announcing four newly authorized on! PLUS pouches, the agency said the pilot had led to faster resolution of issues, less time needed for companies to respond to deficiency letters, and more efficient scientific reviews. It also said it had begun applying lessons from the pilot to other PMTAs. (For background on the brand, see our on! guide.)

What’s reportedly changing

According to the WSJ report, as summarized by trade publication Nicotine Insider, the FDA plans to:

• revisit the 2021 PMTA rule that sets out what applications must contain
• simplify requirements for certain scientific studies
• speed up review timelines

The changes would cover e-cigarettes, nicotine pouches and other tobacco products, not just pouches. The report said the announcement was expected within days, but no formal FDA notice had been published as of September 24, 2026.

The debate

Supporters, mostly the industry and harm-reduction advocates, say the current process is too slow. They argue it has let unauthorized products, including cheap imports, fill store shelves while lower-risk options for adult smokers wait years for a decision. A regulatory executive at retailer Haypp Group USA told Nicotine Insider an overhaul is “not just welcome, it’s necessary”.

Public health groups have long pushed the other way. They argue that the PMTA’s scientific requirements exist to keep youth-appealing products off the market, and that loosening them risks more young people starting on nicotine. We’ll update this post once the FDA publishes the actual changes and formal reactions are on the record.

What it could mean if you buy pouches

• More authorized products, sooner. If reviews get faster, expect more brands, strengths and flavors to get an FDA marketing order rather than sitting in a legal gray area.
• Authorization isn’t a safety rating. An FDA authorization means a product met the public-health standard for being sold. It doesn’t mean it’s safe, and it’s different from a modified-risk claim like the one ZYN received (see our ZYN MRTP explainer).
• State rules still apply. Federal authorization doesn’t override state flavor bans or taxes. Many states now tax pouches heavily (see our state tax guide) and some restrict flavors. Our US legal guide covers the federal and state picture.

Bottom line

The FDA appears to be moving from a slow, all-encompassing review process toward a faster, more focused one. It’s building on a 2025 nicotine pouch pilot that the agency says sped up decisions without lowering its standard. Until the FDA publishes the actual changes, the details are reported plans. If they go ahead, expect more nicotine pouches to be formally authorized in the US over the next year, alongside continued debate over whether faster approvals help adult smokers or put young people at risk.